Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015 …

Psoriatic arthritis (PsA) accounts for around 20% of referrals to the early arthritis clinic and
presents a significant diagnostic and management challenge. Early diagnosis is important to …

Objectives To review the pathophysiology, co-morbidities, and therapeutic options for
psoriasis, psoriatic arthritis and rheumatoid arthritis in order to further understand the …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations …

Objective: To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With
recent therapeutic advances, this is now a goal for treatment and may represent a measure …

Background Early intervention and tight control of inflammation optimise outcomes in
rheumatoid arthritis but these approaches have not yet been studied in psoriatic arthritis. We …

Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …

Objective To assess currently available tools for measurement of enthesitis and to develop a
new instrument specifically for use in psoriatic arthritis (PsA). Methods Twenty‐eight patients …

A psoriatic arthritis (PsA) module was convened at OMERACT 8 in order to achieve
consensus on the core domains that should be included in randomized controlled trials and …

Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic …